]> 2026-04-12T04:08:03-07:00 Ellagic acid 0 en Ellagic Acid, derived from fruits and nuts, is generally considered safe due to its natural origins. It has not been documented to cause specific side effects. However, it's important to note it's still in preclinical and early trial phases, with a focus on cancer prevention rather than treatment. A toxicity level of 1 signifies that it has not been associated with severe harm or side effects, though more extensive clinical research is needed. 2025-01-18T08:20:11Z 2460693.8473495 Ellagic acid 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Ellagic Acid\n\nThis is a family of phenolic compounds present in fruits and nuts, including raspberries,\nblueberries, strawberries, pomegranate juice, and walnuts. In laboratory experiments it\nhas been shown to potently inhibit the growth of various chemical-induced cancers, with\nthe basis of the effect being an arrest of cell division in the G stage, thus\n\ninducing the programmed cell death known as apoptosis. While there have been no trials\nto assess its clinical effects with brain cancer, a recent clinical trial, performed at UCLA\nwith prostate cancer demonstrate its potential (288). Patients with prostate cancer, whose\nPSA levels were rising after initial treatment with either surgery or radiation, drank\npomegranate juice (8 oz\/ daily), which contains high levels of eligitannnins (precursors to\nellagic acid). The dependent measure was the rate of increase in the PSA level, which\ntypically rises at a steady rate for this category of patients. Pomegranate juice produced\n\ufffdan increase in PSA doubling time, from 15 months at baseline to 54 months after\nconsuming the juice. Of the 46 patients in the trial, 85% exhibited a notable increase in\nthe doubling time, and 16% had decreases in their PSA.\n\nFish oil (source of omega-3 fatty acids)\n\nThe major omega-3 fatty acids found in cold-water fish oil, eicosapentaenoic acid (EPA)\nand docosahexaenoic acid (DHA), have also been demonstrated to have potent cytotoxic\neffects on cancer cells in various laboratory experiments. Part of their mechanism of\naction is similar to that of GLA, in that the metabolism of these fatty acids creates high\nlevels of free radicals. In addition, a recent laboratory study has shown that EPA-treated\ntumors showed a significant arrest of cell division due to inhibition of cyclins at the G1\nphase of cell division, which resulted in an increased rate of programmed cell death\nknown as apoptosis (241).\n\nA clinical trial comparing fish-oil supplements versus a placebo has also been reported,\ninvolving patients with several different types of advanced cancer (242). Thirty\nmalnourished patients suffering from cachexia were randomly assigned to receive 18 g of\nfish oil per day or a placebo sugar pill. An additional thirty subjects, adequately\nnourished, received a similar random assignment. For both groups the fish oil\nsignificantly increased survival. For the malnourished patients the median survival times,\nas estimated from their survivor functions, were 110 days for the patients receiving\nplacebo and 210 days for patients in the fish oil group. For the adequately nourished\npatients, the corresponding numbers were 350 versus 500 days.\n\nIn laboratory studies (243) fish oil has also been shown to increase the effectiveness of\nchemotherapy and radiation. A phase II trial involving 25 heavily pretreated metastatic\nbreast cancer patients, used 1.8 g\/day of DHA, one of the two major fatty acids in fish oil,\nin combination with standard anthracycline-based chemotherapy (244). Patients\npreviously had failed both chemotherapy and hormone treatments and many had\nmultiple metastases, including many liver metastases. Because this was a phase II trial,\nthere was no control group that received chemotherapy alone, but patients were\nsubdivided according to their level of plasma DHA. The two groups were approximately\nequal with respect to all major prognostic variables. Median survival for the high DHA\npatients was 34 months, vs. 18 months for the low-DHA patients.\n\nA second clinical trial presented 2200 mg of EPA plus 240 mg of DHA to patients with\nadvanced non small cell lung cancer (245). Patients either received only the standard of\ncare of chemotherapy, or the same treatment in combination with daily fish oil. Response\nrate (tumor regressions) was 60% in the fish oil group and 26% in those receiving only\nthe standard of care. One-year survival was 60% in the fish oil group versus 39% in those\nreceiving only chemotherapy. Chemotherapy toxicity was also decreased in those using\nfish oil."] Ellagic acid# ERRa3f62c6665776505f0db7c26c19aebf1